All sponsors

Bio-Thera Solutions

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS7
PHASE 3 / 2-33
RECRUITING3
READOUTS ≤12 MONTHS3
READOUT SLIPPED >6 MO100%

Delay Index: of 5 active trials registered more than a year ago, 5 have moved their primary completion (readout) date by more than 6 months since first registration (median +29.0 months). See all sponsors →

Open Bio-Thera Solutions on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
Recombinant humanized anti-PD-1 monoclonal antibody injection
NCT06123884
P2/3RecruitingCervical Cancer5262026-09 (+29 mo)
BAT8008 injection
NCT06341114
P1/2Active, not recruitingAdvanced Solid Tumors1122026-11-30 (+8 mo)
Monoclonal antibody BAT6026
NCT06094179
P1/2Active, not recruitingDermatitis, Atopic332026-12-31 (+23 mo)
BAT5906 injection
NCT07515079
P3RecruitingDiabetic Macular Edema (DME)4062027-04-30
BAT4406F Injection
NCT06044350
P2Active, not recruitingOptic Neuromyelitis Spectrum Disease1622027-12-31 (+31 mo)
BAT8010 for Injection
NCT06376136
P1/2Active, not recruitingAdvanced Solid Tumors2182028-02-29 (+45 mo)
BAT4406F
NCT07499700
P2/3RecruitingMinimal Change Disease (MCD); Focal Segmental Glomerulosclerosis (FSGS)1922030-10-26